Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma

Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cancer Jg. 21; H. 1; S. 31 - 15
Hauptverfasser: Huo, Junyu, Wu, Liqun, Zang, Yunjin, Dong, Hongjing, Liu, Xiaoqiang, He, Fu, Zhang, Xiao
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 07.01.2021
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
ISSN:1471-2407, 1471-2407
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. Methods The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. Results A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Conclusion Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
AbstractList Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. Methods The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. Results A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Conclusion Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions. Keywords: Hepatocellular carcinoma, Tumor-associated macrophages, Metabolic, Prognostic, Signature
In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC.BACKGROUNDIn recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC.The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally.METHODSThe study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally.A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4).RESULTSA risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4).Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.CONCLUSIONOur study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. Methods The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. Results A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Conclusion Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. Methods The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. Results A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Conclusion Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
Abstract Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the close relationship of TAMs with metabolic reprogramming genes in hepatocellular carcinoma (HCC) to provide new methods of treatment for HCC. Methods The study selected 343 HCC patients with complete survival information (survival time > = 1 month) in the Cancer Genome Atlas (TCGA) as study subjects. Kaplan-Meier survival analysis assisted in determining the relationship between macrophage infiltration and overall survival (OS), and Pearson correlation tests were used to identify metabolic reprogramming genes (MRGs) associated with tumor macrophage abundance. Lasso regression algorithms were used on prognosis-related MRGs identified by Kaplan-Meier survival analysis and univariate Cox regression analysis to construct a risk score; another independent cohort (including 228 HCC patients) from the International Cancer Genome Consortium (ICGC) was used to verify prognostic signature externally. Results A risk score composed of 8 metabolic genes could accurately predict the OS of a training cohort (TCGA) and a testing cohort (ICGC). The risk score could be widely used for people with different clinical characteristics, and it is a predictor that is independent of other clinical factors that affect prognosis. As expected, compared with the low-risk group, the high-risk group exhibited an obviously higher macrophage abundance, together with a positive correlation between the risk score and the expression levels of three commonly used immune checkpoints (PD1, PDL1, and CTLA4). Conclusion Our study constructed and validated a novel eight-gene signature for predicting HCC patient OS, which may contribute to clinical treatment decisions.
ArticleNumber 31
Audience Academic
Author Zang, Yunjin
He, Fu
Zhang, Xiao
Wu, Liqun
Liu, Xiaoqiang
Dong, Hongjing
Huo, Junyu
Author_xml – sequence: 1
  givenname: Junyu
  surname: Huo
  fullname: Huo, Junyu
  organization: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao University
– sequence: 2
  givenname: Liqun
  orcidid: 0000-0001-8833-909X
  surname: Wu
  fullname: Wu, Liqun
  email: wulq5810@126.com
  organization: Liver Disease Center, The Affiliated Hospital of Qingdao University
– sequence: 3
  givenname: Yunjin
  surname: Zang
  fullname: Zang, Yunjin
  organization: Liver Disease Center, The Affiliated Hospital of Qingdao University
– sequence: 4
  givenname: Hongjing
  surname: Dong
  fullname: Dong, Hongjing
  organization: Liver Disease Center, The Affiliated Hospital of Qingdao University
– sequence: 5
  givenname: Xiaoqiang
  surname: Liu
  fullname: Liu, Xiaoqiang
  organization: Qingdao University
– sequence: 6
  givenname: Fu
  surname: He
  fullname: He, Fu
  organization: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao University
– sequence: 7
  givenname: Xiao
  surname: Zhang
  fullname: Zhang, Xiao
  organization: Linyi Central Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33413205$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1TAQhSMEog_4AyxQJCQEixTbedjZIFVVgUqVkHisrYk9SVwl9sV2LtAd_xzf3tL2VqjxIsn4O2c0o3OQPbbOYpa9oOSIUtG8C5QJUReEkYJwXlbF5aNsn1acFqwi_PGd773sIIQLQigXRDzN9sqyoiUj9X7259QMYywGtJjPGKFzk1F5MIOFuHjMPU4QUec_TRzzuMzOFxCCU-aqOoPybjXCgCFfedRGRWOH3K3RwzTlYfFrs4Yp753PR1xBdAqnaZnA5wq8MtbN8Cx70sMU8Pn1-zD7_uH028mn4vzzx7OT4_NCNZzFohcMRHpo21LgTFdMlR2jbaObUoNqSdcr0XPS0452mldadOkXG8171UJbl4fZ2dZXO7iQK29m8L-lAyOvCs4PEnw0akLZC9RMJ-MSVdWUdaeIUMm7rZnQQKrk9X7rtVq6GbVCG9PAO6a7N9aMcnBrybloa9okgzfXBt79WDBEOZuw2Q1YdEuQrOJN3dQlEQl9dQ-9cIu3aVUbSghSc0ZvqQHSAMb2LvVVG1N53NSkbiva8EQd_YdKR-NsVEpXb1J9R_B2R5CYiL_iAEsI8uzrl1329R12RJjiGNy0RONs2AVf3t3ezdr-pTIBbAukdIXgsb9BKJGb6Mtt9GWKvryKvrxMInFPpEyETfM0o5kelpZbaUh97ID-dsUPqP4C71cZwg
CitedBy_id crossref_primary_10_3389_fonc_2021_635324
crossref_primary_10_3389_fimmu_2022_930352
crossref_primary_10_3389_fgene_2021_561254
crossref_primary_10_3389_fonc_2021_666199
crossref_primary_10_3389_fonc_2021_685026
crossref_primary_10_1007_s12094_024_03698_9
crossref_primary_10_1016_j_coph_2022_102232
crossref_primary_10_3389_fphar_2022_907433
crossref_primary_10_1177_17588359231189436
crossref_primary_10_1186_s12957_021_02202_9
Cites_doi 10.1016/j.canlet.2017.10.037
10.3748/wjg.v20.i24.7971
10.1189/jlb.0609385
10.1038/onc.2009.416
10.21037/jgo.2017.06.09
10.1016/S0959-440X(00)00124-X
10.1016/j.cell.2019.08.052
10.1016/j.jhep.2010.07.044
10.1016/j.critrevonc.2007.07.004
10.1126/science.1252510
10.1093/abbs/gmy009
10.1007/s13277-015-3912-2
10.1186/s13046-019-1396-4
10.3390/cancers6031670
10.1016/j.canlet.2014.05.008
10.1038/s41575-019-0217-8
10.1016/j.cmet.2016.08.011
10.1038/nature22964
10.1016/j.ccr.2012.02.014
10.1155/2016/6058147
10.3892/ijo.2014.2597
10.1093/nar/gkaa407
10.3389/fcell.2018.00138
10.1007/s00432-008-0469-0
10.1126/science.aaa8172
10.3390/molecules25102417
10.1038/nm.3394
10.1007/s00418-008-0530-8
10.1038/nature10350
10.1007/s10555-006-9001-7
10.1016/j.ceb.2017.05.006
10.1038/s41598-017-08128-1
10.1016/j.bbcan.2009.02.004
10.1093/jnci/59.1.29
10.1186/s12885-018-4435-1
10.1158/0008-5472.CAN-17-0307
10.1002/1878-0261.12639
10.1002/hep.29904
10.1038/nature11126
10.1158/1940-6207.CAPR-09-0252
ContentType Journal Article
Copyright The Author(s) 2021
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12885-020-07734-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


Publicly Available Content Database
MEDLINE



Database_xml – sequence: 1
  dbid: DOA
  name: Open Access: DOAJ - Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 15
ExternalDocumentID oai_doaj_org_article_f8ed2dd633ec4635bc08cf709528da04
PMC7789516
A650594167
33413205
10_1186_s12885_020_07734_z
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
AFFHD
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c672t-f82a88881991a72d42c3b2196d63dac90bfc8f70f1b1bd74d8b8f7e6d7fc9a953
IEDL.DBID RSV
ISICitedReferencesCount 13
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000608286700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1471-2407
IngestDate Fri Oct 03 12:44:15 EDT 2025
Tue Nov 04 01:57:21 EST 2025
Sun Nov 09 12:10:56 EST 2025
Mon Oct 06 18:38:28 EDT 2025
Tue Nov 11 07:39:53 EST 2025
Tue Nov 04 17:46:21 EST 2025
Thu Nov 13 14:51:24 EST 2025
Thu May 22 21:06:16 EDT 2025
Thu Apr 03 06:59:13 EDT 2025
Sat Nov 29 06:42:20 EST 2025
Tue Nov 18 19:44:12 EST 2025
Sat Sep 06 07:17:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hepatocellular carcinoma
Metabolic
Tumor-associated macrophages
Prognostic
Signature
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c672t-f82a88881991a72d42c3b2196d63dac90bfc8f70f1b1bd74d8b8f7e6d7fc9a953
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8833-909X
OpenAccessLink https://link.springer.com/10.1186/s12885-020-07734-z
PMID 33413205
PQID 2478805721
PQPubID 44074
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_f8ed2dd633ec4635bc08cf709528da04
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7789516
proquest_miscellaneous_2476565308
proquest_journals_2478805721
gale_infotracmisc_A650594167
gale_infotracacademiconefile_A650594167
gale_incontextgauss_ISR_A650594167
gale_healthsolutions_A650594167
pubmed_primary_33413205
crossref_primary_10_1186_s12885_020_07734_z
crossref_citationtrail_10_1186_s12885_020_07734_z
springer_journals_10_1186_s12885_020_07734_z
PublicationCentury 2000
PublicationDate 2021-01-07
PublicationDateYYYYMMDD 2021-01-07
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-07
  day: 07
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC cancer
PublicationTitleAbbrev BMC Cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2021
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References 7734_CR4
7734_CR30
7734_CR31
7734_CR10
7734_CR32
RT Netea-Maier (7734_CR12) 2018; 413
7734_CR33
G Lorusso (7734_CR2) 2008; 130
7734_CR34
7734_CR35
7734_CR9
7734_CR8
7734_CR7
7734_CR6
S Guo (7734_CR21) 2018
PS Ward (7734_CR11) 2012; 21
Q Gao (7734_CR15) 2019; 179
7734_CR37
7734_CR16
7734_CR38
7734_CR17
7734_CR39
7734_CR18
7734_CR40
7734_CR41
F Kamil (7734_CR13) 2018; 9
7734_CR20
7734_CR42
7734_CR22
7734_CR23
7734_CR24
DF Quail (7734_CR1) 2013; 19
C Yang (7734_CR19) 2020; 14
NCW Lee (7734_CR36) 2018; 6
Whiteside TJO (7734_CR3) 2008
T Chanmee (7734_CR5) 2014; 6
7734_CR25
7734_CR26
L Satriano (7734_CR14) 2019; 16
7734_CR27
7734_CR28
7734_CR29
References_xml – volume: 413
  start-page: 102
  year: 2018
  ident: 7734_CR12
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.10.037
– ident: 7734_CR27
  doi: 10.3748/wjg.v20.i24.7971
– ident: 7734_CR9
  doi: 10.1189/jlb.0609385
– start-page: 5904
  volume-title: The tumor microenvironment and its role in promoting tumor growth
  year: 2008
  ident: 7734_CR3
– ident: 7734_CR24
  doi: 10.1038/onc.2009.416
– volume: 9
  start-page: 180
  issue: 1
  year: 2018
  ident: 7734_CR13
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2017.06.09
– ident: 7734_CR34
  doi: 10.1016/S0959-440X(00)00124-X
– volume: 179
  start-page: 561
  issue: 2
  year: 2019
  ident: 7734_CR15
  publication-title: Cell
  doi: 10.1016/j.cell.2019.08.052
– ident: 7734_CR26
  doi: 10.1016/j.jhep.2010.07.044
– ident: 7734_CR6
  doi: 10.1016/j.critrevonc.2007.07.004
– ident: 7734_CR4
  doi: 10.1126/science.1252510
– ident: 7734_CR37
  doi: 10.1093/abbs/gmy009
– start-page: 2083
  volume-title: Effect of stromal cells in tumor microenvironment on metastasis initiation
  year: 2018
  ident: 7734_CR21
– ident: 7734_CR42
  doi: 10.1007/s13277-015-3912-2
– ident: 7734_CR20
  doi: 10.1186/s13046-019-1396-4
– volume: 6
  start-page: 1670
  issue: 3
  year: 2014
  ident: 7734_CR5
  publication-title: Cancers
  doi: 10.3390/cancers6031670
– ident: 7734_CR22
  doi: 10.1016/j.canlet.2014.05.008
– volume: 16
  start-page: 748
  issue: 12
  year: 2019
  ident: 7734_CR14
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0217-8
– ident: 7734_CR32
  doi: 10.1016/j.cmet.2016.08.011
– ident: 7734_CR41
  doi: 10.1038/nature22964
– volume: 21
  start-page: 297
  issue: 3
  year: 2012
  ident: 7734_CR11
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.02.014
– ident: 7734_CR23
  doi: 10.1155/2016/6058147
– ident: 7734_CR38
  doi: 10.3892/ijo.2014.2597
– ident: 7734_CR16
  doi: 10.1093/nar/gkaa407
– volume: 6
  start-page: 138
  year: 2018
  ident: 7734_CR36
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2018.00138
– ident: 7734_CR25
  doi: 10.1007/s00432-008-0469-0
– ident: 7734_CR31
  doi: 10.1126/science.aaa8172
– ident: 7734_CR33
  doi: 10.3390/molecules25102417
– volume: 19
  start-page: 1423
  issue: 11
  year: 2013
  ident: 7734_CR1
  publication-title: Nat Med
  doi: 10.1038/nm.3394
– volume: 130
  start-page: 1091
  issue: 6
  year: 2008
  ident: 7734_CR2
  publication-title: Histochem Cell Biol
  doi: 10.1007/s00418-008-0530-8
– ident: 7734_CR17
  doi: 10.1038/nature10350
– ident: 7734_CR8
  doi: 10.1007/s10555-006-9001-7
– ident: 7734_CR10
  doi: 10.1016/j.ceb.2017.05.006
– ident: 7734_CR29
  doi: 10.1038/s41598-017-08128-1
– ident: 7734_CR7
  doi: 10.1016/j.bbcan.2009.02.004
– ident: 7734_CR35
  doi: 10.1093/jnci/59.1.29
– ident: 7734_CR28
  doi: 10.1186/s12885-018-4435-1
– ident: 7734_CR18
  doi: 10.1158/0008-5472.CAN-17-0307
– volume: 14
  start-page: 896
  issue: 4
  year: 2020
  ident: 7734_CR19
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12639
– ident: 7734_CR30
  doi: 10.1002/hep.29904
– ident: 7734_CR39
  doi: 10.1038/nature11126
– ident: 7734_CR40
  doi: 10.1158/1940-6207.CAPR-09-0252
SSID ssj0017808
Score 2.3814104
Snippet Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to...
In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to explore the...
Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study aims to...
Abstract Background In recent years, the relationship between tumor-associated macrophages (TAMs) and solid tumors has become a research hotspot. This study...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 31
SubjectTerms Abundance
Aged
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Cellular Reprogramming - genetics
Correlation analysis
CTLA-4 protein
Datasets
Female
Follow-Up Studies
Gene expression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genetic aspects
Genetics
Genomes
genomics and epigenetics
Health aspects
Health Promotion and Disease Prevention
Hepatocellular carcinoma
Hepatoma
Humans
Immune checkpoint
Liver cancer
Liver Neoplasms - genetics
Liver Neoplasms - metabolism
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Macrophages
Male
Medical prognosis
Medicine/Public Health
Metabolic
Metabolic regulation
Metabolism
Metabolites
Metastases
Metastasis
Oncology
Patients
PD-1 protein
Prognosis
Prognostic
Regression analysis
Research Article
Risk groups
Signature
Solid tumors
Surgical Oncology
Survival analysis
Survival Rate
Tumor-associated macrophages
Tumor-Associated Macrophages - metabolism
Tumor-Associated Macrophages - pathology
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJtAAYOQOEDUxHnYORbUCg5UiIfUm-VX2JV2k2qTcOiNf86M44SmCLhw3HiySmYm48_2zDeEvBCFViI1OnZlmcQ5OE1cGe2wUBfwuXCAYpVvNsFPTsTpafXxQqsvzAkb6YFHxR3UwllmbZllzuQwO2qTCFNzQAZMWDUygQLqmRZT4fyAi0RMJTKiPOggCgusRE7ihPMsj88X05Bn6_89Jl-YlC4nTF46NfWT0fFNciOgSHo4Pv0tcsU1t8m1D-Gc_A75ceT5QcA5HN26Hgy9WRuKuRqex5P6ChZnKe7C0n7YtrtYBTvB1a3Cvl4riDQdPdvhn2JuNMVkT7XZ0G6A8AIOSgHv0hVMZ32L2_-Yz0oNtiZq2q26S74eH315-y4OzRZiU3LWx7VgClbDAlOhFGc2ZybTEM5KUL1Vpkp0bQTovU51qi3PrdDw05WW16ZSVZHdI3tN27gHhOaZqhPDUs1UnVtY0WmYBnnGslw4Y00akXTSvTSBiRwbYmykX5GIUo72kmAv6e0lzyPyar7nbOTh-Kv0GzTpLIkc2v4CeJYMniX_5VkReYoOIceC1DkSyEMAtUUFQJZH5LmXQB6NBhN1vqmh6-T7z58WQi-DUN3CWxoV6h5AV0i9tZDcX0jCh26Ww5NnyhBoOsmw_QFgbgZafTYP452YPNe4dvAygNqLLBERuT868qyZDFEMS4qI8IWLL1S3HGnWK09DzrkAeF5G5PX0Mfx6rD-b5uH_MM0jcp1hbhFuhfF9stfvBveYXDXf-3W3e-JDwU87LWPn
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Publicly Available Content Database
  dbid: PIMPY
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZgixAX3o9AAYOQONBoE-dh54QKakUPrSoeUjlZju10K-0myybLoTf-OTOONyVF9MRx48nu2h5_nrFnviHkjchKJWJdhjbPozAFpQkLXVpM1AX7XFiwYpUrNsGPjsTJSXHs06NbH1a5wUQH1D3bM8ZtAwhPTaPxxHzKkPUdTA0Wv1_-CLGGFN61-oIa18kWEm-JCdk6Pjg8_j7cKnARiU3ijMinLWCzwPzkKIw4T9LwfLQ5OQ7_v5H6j63qchjlpbtUt0Xt3_m_nbtLbntTle72unWPXLP1fXLz0F_GPyC_9hwJCWigpQvbgTbBr1AMCHFkodSlyVhD8aiXdutFswqVVwZ4ulBYPGwGcNbS5Qq_FAOwKUaUqvmctmvAMFgFFIxqOoM9s2vwjgGDZqnG-kd1s1APybf9va8fP4W-okOoc866sBJMgcstMN5KcWZSppMSMDM3eWKULqKy0qLiURWXcWl4akQJH21ueKULVWTJIzKpm9o-ITRNVBVpFpdMVakBt7GEvZYnLEmF1UbHAYk3Uym1pzvHqhtz6dwekct--iVMv3TTL88D8m54Z9mTfVwp_QE1ZJBEom73oFmdSr_uZSWsYQa6l1idgnFX6kho6GGRMWFUlAbkJeqX7LNeB7iRu2A5ZwVYyzwgr50EknXUGA10qtZtKw--fB4JvfVCVQO91MonV8BYIb_XSHJ7JAloosfNGw2VHs1aeaGQAXk1NOObGKFX22btZMA1yJJIBORxvy6GkUnQVGJRFhA-WjGjoRu31Gczx3XOuQAfIA_IzmZtXfytf0_N06t78YzcYhiahCdpfJtMutXaPic39M_urF298KjxGxYNfns
  priority: 102
  providerName: ProQuest
Title Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma
URI https://link.springer.com/article/10.1186/s12885-020-07734-z
https://www.ncbi.nlm.nih.gov/pubmed/33413205
https://www.proquest.com/docview/2478805721
https://www.proquest.com/docview/2476565308
https://pubmed.ncbi.nlm.nih.gov/PMC7789516
https://doaj.org/article/f8ed2dd633ec4635bc08cf709528da04
Volume 21
WOSCitedRecordID wos000608286700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: Open Access: BioMedCentral Open Access Titles
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: Open Access: DOAJ - Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RSV
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoixAX3o9AWQxC4gARifOwc2zRVvTQ1WoLqJwsx3a6K-0m1SbLoTf-OTPeJJDykOCyUuLxKh6PZz7b8yDklUhyJUKd-zZNAz8GofEznVsM1AV8LiygWOWKTfDJRJydZdM2KKzuvN27K0mnqd2yFum7GjSpwGjiwA84j2L_cofsgbkTuBxnp5_7uwMuAtGFx_y238AEuUz9v-rjnwzSVWfJKzemzhAd3f6_Idwht1rgSQ-2knKXXLPlPXLjpL1av0--jV1KEZAnS1e2AdlYLjRF9w6X-pO6oBdrKB7c0mazqta-aqcW3q4UlgKbg3Kq6cUa_xTdqSn6h6rlktYb0Egg0xQgMp2DBWwqvDFAF1iqsZpRWa3UA_LpaPzx_Qe_rc_g65Szxi8EU7CBFug9pTgzMdNRDhowNWlklM6CvNCi4EER5mFueGxEDo82NbzQmcqS6CHZLavSPiY0jlQRaBbmTBWxgU1gDpaTRyyKhdVGhx4JuymTuk1ejjU0ltJtYkQqt7yVwFvpeCsvPfKm73OxTd3xV-pDlISeEtNuuxfV-ly2q1gWwhpmYHiR1TFAtVwHQsMIs4QJo4LYI89RjuQ2hrVXHvIAcHCSAfblHnnpKDD1Rom-PedqU9fy-HQ2IHrdEhUVjFKrNlQCeIXZugaU-wNK0A162NwJtGx1Uy0ZVkwAmM6Aqy_6ZuyJ_nalrTaOBoB-EgXCI4-28t9zJkLgw4LEI3ywMgasG7aUi7nLXM65AESfeuRttz5-fNafp-bJv5E_JTcZOh7hORnfJ7vNemOfkev6a7Oo1yOyw8-4-xUjsnc4nkxnI3cQA0_T45Ppl5HTJt8BGd9ujA
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqgoAL70egUINAHCBq4mRj54BQgVZd9SEErbQ349hOd6XdZNlkQfTGH-I3MuNNtqSI3nrguMkkWjszn2fsb2YIeS56mRKhznybJIEfg9L4qc4sJuqCfy4seLHKNZvgBwdiMEg_rpBfbS4M0ipbTHRAbUqNe-QbDOu8g3PBwrfTrz52jcLT1baFxkItdu2P7xCyVW_6H-D7vmBse-vw_Y7fdBXwdcJZ7eeCKQj7BHJ-FGcmZjrKwG4Tk0RG6TTIci1yHuRhFmaGx0Zk8NMmhuc6VSl2iQDIvwQ4zpFCxgfLAC_kIhBtYo5INirAfoH5z4EfcB7F_kln8XM9Av5eCf5YCs_SNM-c1bolcPvG_zZ5N8n1xtmmmwvruEVWbHGbXNlv6AR3yM8tV0YFbMjSia3BHsYjTZHS4sqdUpfoYw3FzWpazyflzFeNOsPVicL2Z0MA5IpOZ_hSpJBT5MSq8ZhWc0BhsGMKYQEdwqpfl3hKgrRfqrGDU1FO1F1ydCETcI-sFmVhHxAaRyoPNAszpvLYQOCbgbfAIxbFwmqjQ4-ErbJI3RRsx74hY-kCN5HIhYJJUDDpFEyeeOTV8pnpolzJudLvUAeXklhq3F0oZ8eyQS6ZC2uYgeFFVsfgnmY6EBpGmPaYMCqIPbKOGiwXebtLwJSb4Pv3UvD3uUeeOQksN1Ign-lYzatK9j9_6gi9bITyEkapVZMeAnOFFco6kmsdScBD3b3d2oBs8LiSpwbgkafL2_gkcgwLW86dDAQ3vSgQHrm_sLzlzETo7LGg5xHescnO1HXvFKOhq9bOuYAoJvHI69Z6T__Wvz_Nw_NHsU6u7hzu78m9_sHuI3KNIdEK9wX5GlmtZ3P7mFzW3-pRNXviEIqSLxdt1b8BzvPPow
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3JbtQw1IKCKi7sS6BQg5A4QNTEWewcC3REBYwqCqg3y7GdzkgzySjJcOiNP-c9JxOaskiI48TP0fj5rXkbIc9FkisR6ty3aRr4MRCNn-ncYqEu2OfCghWr3LAJPp2Kk5Ps6FwVv8t234Qku5oG7NJUtnsrU3QsLtK9BqSqwMriwA84j2L_7DK5EuPQIPTXj78OcQQuArEplfntvpE6cl37f5XN55TTxcTJC9FTp5QmN_7_ODfJ9d4gpfsdBd0il2x5m2x_7EPud8j3A9dqBOjM0qVtgWYWc00x7cO1BKWuGMYaih90abteVrWv-iuHp0uFI8JmILQauqrxpZhmTTFvVC0WtFmDpAJap2A60xloxrbCSAKmxlKNU47Kaqnuki-Tg89v3vn93AZfp5y1fiGYAsdaYFaV4szETEc5SMbUpJFROgvyQouCB0WYh7nhsRE5_LSp4YXOVJZE98hWWZX2AaFxpIpAszBnqogNOIc5aFQesSgWVhsdeiTcXJ_UfVNznK2xkM65EanscCsBt9LhVp555OWwZ9W19Pgr9GukigES23G7B1V9KnvuloWwhhk4XmR1DCZcrgOh4YRZwoRRQeyRXaQp2dW2DkJF7oN9nGRgE3OPPHMQ2JKjxJyfU7VuGnl4_GkE9KIHKio4pVZ9CQXgCrt4jSB3RpAgM_R4eUPcspdZjWQ4SQHMdwZYfTos407MwytttXYw4AAkUSA8cr_jhQEzERpELEg8wkdcMkLdeKWcz1xHc84FWPqpR15teOXn3_rz1Tz8N_Bdsn30diI_HE7fPyLXGOYm4ac0vkO22nptH5Or-ls7b-onToT8ABQHdEQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eight-gene+metabolic+signature+related+with+tumor-associated+macrophages+predicting+overall+survival+for+hepatocellular+carcinoma&rft.jtitle=BMC+cancer&rft.au=Huo%2C+Junyu&rft.au=Wu%2C+Liqun&rft.au=Zang%2C+Yunjin&rft.au=Dong%2C+Hongjing&rft.date=2021-01-07&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft.spage=31&rft_id=info:doi/10.1186%2Fs12885-020-07734-z&rft_id=info%3Apmid%2F33413205&rft.externalDocID=33413205
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon